Reata Pharmaceuticals Inc - Class A
RETA
Market Cap$0
Close$
$188.61
9.4% upside
Current Fair Value
9.4% upsideUndervalued by 9.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-257,084,000.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.31 |
| Beta | 0.0 |
| Outstanding Shares | 33,587,596 |
| Avg 30 Day Volume | 0 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | -0.0 |
| Price to Sales | - |
| Price to Book Ratio | 86.18 |
| Enterprise Value to Revenue | -10.95 |
| Enterprise Value to EBIT | 0.75 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | -0.28 |
| Debt to Equity | 0.84 |
Revenue Sources
No data
ESG Score
No data
About Reata Pharmaceuticals Inc
CEO: J. Warren Huff